Both peptides are animal-data-dominant, share zero published human RCTs as of July 2026, are WADA-prohibited at all times, and are mechanistically complementary rather than redundant. This page synthesizes the existing research summaries into a single scannable reference.
Both peptides share zero published human RCTs as of July 2026. The body of evidence for BPC-157 and TB-500 is preclinical — animal models and cell studies. This page synthesizes the existing BPC-157 deep-dive and TB-500 deep-dive; it does not introduce new evidence. If you are evaluating one peptide for a clinical decision, the underlying deep-dives are the authoritative references.
Each row states a claim that is supported by a specific peer-reviewed citation. PMIDs link to the corresponding PubMed record — open any of them to verify the underlying study directly. Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal/preclinical → mechanistic/anecdote).
| Claim | BPC-157 evidence | TB-500 evidence |
|---|---|---|
| Sustainable, consistent body of preclinical data | Strong (animal)Pharmacological profile across GI, tendon, vascular, and wound models. PMID: 34139902 | Moderate (animal)Original actin-mechanism description and downstream wound-healing studies. PMID: 2642584 |
| Tendon / ligament repair | Supportive (animal)Tendon, ligament, and bone healing consistently reported across rodent studies. PMID: 32628526 · PMID: 31800443 | Limited (animal)TB-500 alone shows some benefit; stronger signal in combination with BPC-157. PMID: 29940968 |
| Wound healing / cell migration | Supportive (animal)Wound repair via angiogenic and EGR-1 pathways; foundational NO-pathway mechanism. PMID: 9493769 | Strong (animal)Accelerated wound closure with improved collagen architecture across multiple rodent models. PMID: 10496477 · PMID: 16841073 |
| Cardioprotection | Preliminary (animal)NO-pathway involvement plausibly relevant; no dedicated cardiac studies to date. | Moderate (animal)Reduced infarct size and improved cardiac function in rodent MI models. PMID: 14630500 |
| Human randomized controlled trial | NoneZero published human RCTs as of July 2026. | NoneZero published human RCTs as of July 2026. |
| WADA status | Prohibited (S0) | Prohibited (S0) |
| FDA status | Not approved; excluded from 503A compounding | Not approved; orphan-drug designation (corneal only) |
Citations reused from the BPC-157 deep-dive and the TB-500 deep-dive. No new PMIDs introduced — the underlying studies are the same ones reviewed in those pages.
Three side-by-side cards for direct comparison. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human trial supports them.
Three honest verdicts. Each mirrors the same evidence-gap framing used in the underlying deep-dives — choosing one peptide over another does not establish human efficacy for either, it only frames where the animal evidence is strongest.
The Sikiric lab's tendon and MSK data is the most extensive of any peptide commonly discussed in recovery communities. The mechanistic story — VEGF-driven angiogenesis + EGR-1 collagen signaling — is biologically plausible and consistent across multiple animal models. Caveats: zero human RCTs as of 2026, and the evidence base is dominated by a single research group at the University of Zagreb with disclosed patent interests. Animal-to-human translation is not assumed.
TB-500's actin-reorganization mechanism has been replicated across multiple independent labs for wound closure and collagen architecture. The cardioprotective hypothesis (PMID 14630500) is the most-cited mechanistic rationale but remains entirely preclinical. Caveats: zero human RCTs for any systemic or musculoskeletal application; orphan-drug designation is for corneal wounds only and has not progressed to a completed trial; endogenous production complicates doping detection.
Animal-model evidence for BPC-157 + TB-500 is more compelling than for either alone, particularly in tendon and ligament repair (PMID: 29940968). The peptide communities frequently select this stack on the rationale that BPC-157 builds blood supply while TB-500 drives cell migration — they hit different points in the healing cascade. Caveats: still animal-only, no human trials. Combined risk profile is unknown. Both are WADA-prohibited (S0) — the combination does not change the regulatory status.
"Evidence tier" is the most important field in every claim above. Two peptides can share a use case while having radically different evidence behind that use case. The badge colors map to the same four-tier language used across all PeptideDecoded deep-dives:
For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.
This comparison is the synthesis. The full evidence reviews are the underlying references — open either one if you want to evaluate a specific claim, verify a citation, or read the COI disclosure in detail.
Competitive athletes (WADA S0): both peptides are prohibited at all times — in-competition and out-of-competition. A positive test results in a ban. There is no Therapeutic Use Exemption (TUE) pathway for either compound.
Anyone seeking an FDA-approved therapy: neither BPC-157 nor TB-500 is approved for any human indication. BPC-157 is excluded from 503A compounding under FDA Category 2. TB-500 holds corneal-only orphan-drug designation that has not progressed to a completed trial.
Anyone needing proven human efficacy: there are zero published human RCTs for either peptide as of July 2026. Community-reported outcomes are not clinical evidence. If you need a therapy with validated human efficacy, neither peptide is the right starting point.
This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.